Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06246110 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC
A Phase 2 study of NSCLC, sponsored by Eikon Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 70
- Enrollment target
- 20
- Study locations
NCT06246110 is a Phase 2 study of NSCLC that is actively recruiting participants, run by Eikon Therapeutics. The registered enrollment target is 70 participants, below the 223-participant average among 71 other NSCLC trials with a reported enrollment target (69% lower). The trial reports 20 study locations across 10 states.
The verdict
NCT06246110, a Phase 2 study of NSCLC, is actively recruiting participants, sponsored by Eikon Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 70 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is for patients with advanced/metastatic non-small cells lung cancer (NSCLC) who have not received any treatment through the vein for the advanced disease.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Carboplatin
- DRUG Pemetrexed
- DRUG Paclitaxel
- DRUG EIK1001
Study Locations (20)
California
- California Cancer Care Associates for Research & Excellence - Fresno
- California Research Institute - Los Angeles
- University of Southern California, Norris Comprehensive Cancer Center - Los Angeles
- Providence St Joseph Hospital, Center for Cancer Prevention and Treatment - Orange
- Sutter Health Institute for Medical Research - Sacramento
Florida
- Bioresearch Partner - Hialeah
- Memorial Cancer Institute - Hollywood
- Mid-Florida Hematology and Oncology Center - Orange
- Orlando Health Cancer Institute - Orlando
- Moffitt Cancer Center - Tampa
Illinois
- Illinois Cancer Specialists - Niles
- Accelacare of Duly - Tinley Park
Kansas
- Health Midwest Oncology Associates of Kansas - Overland Park
- Cancer Center of Kansas - Wichita
Alabama
- Southern Cancer Care - Daphne
Arizona
- Ironwood Cancer and Research Center - Chandler
Colorado
- Rocky Mountain Cancer - Lone Tree
Georgia
- Atlanta Piedmont Hospital - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2024-02-06 |
| Est. Completion | 2027-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06246110
The ClinicalTrials.gov registry entry for NCT06246110 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 223-participant average among 71 other NSCLC trials with a reported enrollment target (69% lower). The listed sponsor is Eikon Therapeutics, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with NSCLC appearing as the primary indexed condition, and to 5 interventions - of which Pembrolizumab is the first listed.
NCT06246110 reports 20 study locations spanning 10 distinct geographic areas - top geographies include California, Florida, Illinois.
Frequently Asked Questions
What is clinical trial NCT06246110 about?
NCT06246110 is a clinical study titled "A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC". This study is for patients with advanced/metastatic non-small cells lung cancer (NSCLC) who have not received any treatment through the vein for the advanced disease.
What is the current status of trial NCT06246110?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 70 participants. The study started on 2024-02-06. Estimated completion is 2027-12.
What conditions does trial NCT06246110 study?
This clinical trial studies the following conditions: NSCLC.
What interventions are being tested in trial NCT06246110?
The interventions under investigation include: Pembrolizumab (DRUG), Carboplatin (DRUG), Pemetrexed (DRUG), Paclitaxel (DRUG), EIK1001 (DRUG).
Who is sponsoring clinical trial NCT06246110?
This trial is sponsored by Eikon Therapeutics, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06246110 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for NSCLC
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
RECRUITING · Phase 2
-
A Study of BIO 300 and Thoracic Radiation Therapy in People With Non-Small Cell Lung Cancer and Interstitial Lung Disease
RECRUITING · Phase 2
-
Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
RECRUITING · Phase 2
-
A Study of Targeted Radiation Therapy in People With Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Thoracic Radiotherapy and Inhibition of PD-1 and LAG-3 for Locally Advanced Non-Small Cell Lung Cancer
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.